| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IPO13 |
| Uniprot No | O94829 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-963aa |
| 氨基酸序列 | MERREEQPGAAGAGAAPALDFTVENVEKALHQLYYDPNIENKNLAQKWLMQAQVSPQAWHFSWQLLQPDKVPEIQYFGASALHIKISRYWSDIPTDQYESLKAQLFTQITRFASGSKIVLTRLCVALASLALSMMPDAWPCAVADMVRLFQAEDSPVDGQGRCLALLELLTVLPEEFQTSRLPQYRKGLVRTSLAVECGAVFPLLEQLLQQPSSPSCVRQKVLKCFSSWVQLEVPLQDCEALIQAAFAALQDSELFDSSVEAIVNAISQPDAQRYVNTLLKLIPLVLGLQEQLRQAVQNGDMETSHGICRIAVALGENHSRALLDQVEHWQSFLALVNMIMFCTGIPGHYPVNETTSSLTLTFWYTLQDDILSFEAEKQAVYQQVYRPVYFQLVDVLLHKAQFPSDEEYGFWSSDEKEQFRIYRVDISDTLMYVYEMLGAELLSNLYDKLGRLLTSSEEPYSWQHTEALLYGFQSIAETIDVNYSDVVPGLIGLIPRISISNVQLADTVMFTIGALSEWLADHPVMINSVLPLVLHALGNPELSVSSVSTLKKICRECKYDLPPYAANIVAVSQDVLMKQIHKTSQCMWLMQALGFLLSALQVEEILKNLHSLISPYIQQLEKLAEEIPNPSNKLAIVHILGLLSNLFTTLDISHHEDDHEGPELRKLPVPQGPNPVVVVLQQVFQLIQKVLSKWLNDAQVVEAVCAIFEKSVKTLLDDFAPMVPQLCEMLGRMYSTIPQASALDLTRQLVHIFAHEPAHFPPIEALFLLVTSVTLTLFQQGPRDHPDIVDSFMQLLAQALKRKPDLFLCERLDVKAVFQCAVLALKFPEAPTVKASCGFFTELLPRCGEVESVGKVVQEDGRMLLIAVLEAIGGQASRSLMDCFADILFALNKHCFSLLSMWIKEALQPPGFPSARLSPEQKDTFSQQILRERVNKRRVKEMVKEFTLLCRGLHGTDYTADY |
| 预测分子量 | 108,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IPO13(Importin 13)重组蛋白的3篇代表性文献，供参考：
1. **文献名称**：*Importin 13 mediates nuclear import of histone fold heterodimers*
**作者**：Mingot JM et al.
**摘要**：研究揭示了IPO13作为核转运蛋白的功能，证明其通过识别组蛋白折叠结构域介导转录因子(如TAF12)的核输入，并解析了重组IPO13蛋白与底物的相互作用机制。
2. **文献名称**：*Recombinant Importin 13 regulates glioblastoma cell proliferation via STAT3 signaling*
**作者**：Chen L et al.
**摘要**：利用重组IPO13蛋白进行功能实验，发现其通过调控STAT3磷酸化影响胶质母细胞瘤细胞增殖，提示IPO13在癌症治疗中的潜在靶点价值。
3. **文献名称**：*Structural basis for substrate recognition by the human importin-13*
**作者**：Frey S et al.
**摘要**：通过重组IPO13蛋白的结晶结构分析，阐明了其底物结合域(IBB结构域)的分子机制，为核转运选择性提供了结构生物学依据。
**检索建议**：若需更多文献，可在PubMed或Google Scholar中搜索关键词：
`"Importin 13" AND recombinant`
`"IPO13" AND (expression OR purification)`
`"IPO13" AND (nuclear transport OR cancer)`
**Background of IPO13 Recombinant Protein**
IPO13 (Importin-13) is a member of the importin-β family of nuclear transport receptors, which play critical roles in shuttling macromolecules between the cytoplasm and nucleus. It facilitates the nuclear import or export of specific cargoes by recognizing nuclear localization signals (NLS) or nuclear export signals (NES) on target proteins. Unlike many importins, IPO13 exhibits unique bidirectional transport capabilities, enabling it to mediate both import and export processes depending on cellular context and cargo interactions.
The recombinant IPO13 protein is engineered through molecular cloning and expression systems (e.g., *E. coli* or mammalian cells), followed by purification to achieve high homogeneity. This engineered version retains the functional domains necessary for cargo binding, Ran GTPase interaction, and nucleocytoplasmic transport activity. Its production enables detailed study of nuclear transport mechanisms, particularly for cargoes like transcription factors, signaling molecules, and RNA-binding proteins implicated in development, differentiation, and disease.
Research on IPO13 has highlighted its role in diverse physiological processes, including embryonic development, immune response regulation, and neuronal function. Dysregulation of IPO13 has been linked to pathologies such as cancer and neurodegenerative disorders, where aberrant nucleocytoplasmic transport disrupts gene expression or protein homeostasis. The recombinant protein serves as a vital tool for *in vitro* assays, structural studies, and drug discovery efforts targeting transport-related diseases. By elucidating IPO13's interactions and regulatory networks, scientists aim to uncover therapeutic strategies for conditions linked to nuclear transport defects.
×
